GlassScriptPhysician profile
Jennifer B Blattner
NPI 1811291958
$23,660.19
in general payments reported to CMS, 2019-2025
33 companies · $9,316 in 2025
The $9,316 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,395 · 2022: $2,459 · 2023: $4,688 · 2024: $4,801 · 2025: $9,316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,900 · Education: $808 · Consulting Fee: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,597.72 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,900.00 |
| Education | $807.82 |
| Consulting Fee | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $4,859.73 | 2021-2025 | Aklief, Nemluvio, Oracea |
| Abbvie INC. | $3,263.76 | 2021-2025 | |
| Janssen Biotech, INC. | $1,711.88 | 2021-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $1,221.47 | 2022-2025 | Sotyktu |
| Journey Medical Corporation | $1,048.95 | 2021-2025 | |
| Amgen INC. | $981.69 | 2021-2025 | Otezla, Otezla, Enbrel |
| Arcutis Biotherapeutics, INC. | $969.32 | 2023-2025 | Zoryve |
| Incyte Corporation | $963.79 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $926.49 | 2021-2025 | Ilumya |
| Janssen Scientific Affairs, LLC | $923.76 | 2021-2024 | Tremfya |
| Genzyme Corporation | $923.73 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $831.17 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $593.62 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $593.05 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $560.49 | 2021-2025 | Jublia, Arazlo, Cabtreo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $529.88 | 2021-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $433.07 | 2021-2025 | Adbry |
| Dermavant Sciences, INC. | $381.24 | 2022-2024 | Vtama |
| Almirall LLC | $310.61 | 2021-2025 | Klisyri, Seysara |
| Novartis Pharmaceuticals Corporation | $291.48 | 2024-2025 | |
| Epi Health, LLC | $204.53 | 2021-2022 | |
| Organon LLC | $184.97 | 2025 | Vtama, Nexplanon |
| Allergan, INC. | $151.45 | 2021-2022 | |
| Botanix Sb INC | $151.28 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $126.14 | 2021-2025 | |
| Lnhc, INC | $107.51 | 2025 | Zelsuvmi |
| Fresenius Kabi USA, LLC | $107.38 | 2023-2024 | Idacio |
| Sanofi-Aventis U.S. LLC | $99.99 | 2022 | |
| Verrica Pharmaceuticals INC. | $57.93 | 2023-2025 | Ycanth |
| Sebela Pharmaceuticals INC. | $53.57 | 2022-2023 | Naftin |
| Vyne Pharmaceuticals INC. | $37.32 | 2021 | |
| Biofrontera INC. | $35.41 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Boston Scientific Corporation | $23.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Blattner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.